Shanghai Yituo Pharmaceutical Technology

Shanghai Yituo Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in China that focuses on the development of innovative small molecule drugs for metabolic and inflammatory diseases. The company's lead candidate, ET-01, is a potent and selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. By targeting the renal reabsorption of uric acid, Yituo aims to provide more effective and safer therapeutic options for patients with chronic gout. The company is currently advancing its pipeline through clinical trials in China, positioning itself as a specialized player in the metabolic disease space.